Results 131 to 140 of about 8,597,475 (170)

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report. [PDF]

Ophthalmol Ther
Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M.   +18 more
europepmc   +1 more source

SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration. [PDF]

Eye (Lond)
Bailey C, Lange C, Chaudhary V, Lanzetta P, Oubraham H, Kirchner M, Machewitz T, Allmeier H, Zhang X, Hasanbasic Z, Munk MR, SPECTRUM study investigators.   +11 more
europepmc   +1 more source

Early intraocular pressure dynamics following aflibercept 8 mg versus aflibercept 2 mg: a propensity score-matched analysis

Eye
To compare early intraocular pressure (IOP) dynamics following intravitreal injections of aflibercept 8 mg versus aflibercept 2 mg using propensity score-matched analysis with fellow eye controls.This prospective observational study included treatment-naïve patients with neovascular age-related macular degeneration (AMD) or diabetic macular oedema (DMO)
Sarao V., Veritti D., Bonini F., Martin A. A., Lanzetta P.   +4 more
openaire   +3 more sources

Cost Analysis of Aflibercept 8 mg Versus Aflibercept 2 mg for the Treatment of Diabetic Macular Edema in the PHOTON Trial

Journal of VitreoRetinal Diseases
Purpose: To compare the direct and indirect costs of aflibercept 8 mg with aflibercept 2 mg in patients with diabetic macular edema (DME) using the published data from the PHOTON trial. Methods: Three groups of patients with DME were ...
Celine Chaaya, Stephanie Zhang, Samantha E. Hoffman, Anshul Bhatnagar, Sandra Hoyek, Ryan Sameen Meshkin, Nicolas A. Yannuzzi, Hasenin Al-Khersan, Nimesh A. Patel   +8 more
openaire   +2 more sources

Extended duration of VEGF inhibition with aflibercept 8 mg: the role of reduced ocular clearance

Graefe's Archive for Clinical and Experimental Ophthalmology
Key messages: What is known • Anti-VEGF therapy is the cornerstone of neovascular AMD treatment, but frequent intravitreal injections are required due to the short half-life and rapid ocular clearance of these agents. What is new • The newly available 8 mg aflibercept formulation exhibits a 34.4% slower ocular clearance compared to the standard 2 mg ...
Daniele Veritti, Valentina Sarao, Paolo Lanzetta   +2 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Aflibercept 8 mg/0.07 mL (Eylea HD)

Canadian Journal of Health Technologies
Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the ...
openaire   +2 more sources

Early Outcome of Aflibercept 8 mg for Neovascular AMD in the Real-world Setting

Klinische Monatsblätter für Augenheilkunde
Abstract Purpose To investigate the early outcome of intravitreal aflibercept 8 mg in treating neovascular age-related macular degeneration (nAMD) of eyes that either received prior intravitreal anti-VEGF treatment or were treatment-naïve – under real-world conditions. Methods This is a retrospective study of a total
Michael Grün, Kai Rothaus, Albrecht Peter Lommatzsch, Henrik Faatz   +3 more
openaire   +2 more sources

Switching From Aflibercept 2 mg to 8 mg in Vitrectomized Eyes With Neovascular Age-Related Macular Degeneration

Cureus
Vitrectomy may alter intravitreal pharmacokinetics through the removal of the vitreous gel, potentially accelerating the clearance of anti-vascular endothelial growth factor (VEGF) agents. Clinical trials and most real-world studies on neovascular age-related macular degeneration (nAMD) generally exclude vitrectomized eyes, and the efficacy of anti ...
Ryuto, Tamai, Tomohiro, Nizawa, Yuto, Kawamata, Takehito, Iwase, Takayuki, Baba   +4 more
openaire   +2 more sources

REAL-WORLD DURABILITY OF AFLIBERCEPT 8 MG AND FARICIMAB IN INITIATORS VERSUS SWITCHERS

Retina
Purpose: To evaluate real-world differences in treatment durability, functional, and anatomic outcomes in patients who initiated or switched to aflibercept 8 mg or faricimab. Methods: Patients were categorized into four cohorts: 1 ...
Richard N. Sather, Trent Chiang, Jade Y. Moon, Sundeep Dev, Peter J. Belin   +4 more
openaire   +2 more sources

Current use of aflibercept 8 mg (eylea HD) in retinal diseases

Archives of Ophthalmological Research
Aflibercept 8 mg (Eylea HD) has emerged as a pivotal agent in the treatment of retinal diseases and has begun to showcase its efficacy and innovation in the field of ophthalmology. This article delves into the current use of aflibercept 8 mg, exploring its applications, mechanisms of action, and impact on the treatment landscape for various retinal ...
openaire   +1 more source